JP2006506425A5 - - Google Patents

Download PDF

Info

Publication number
JP2006506425A5
JP2006506425A5 JP2004552562A JP2004552562A JP2006506425A5 JP 2006506425 A5 JP2006506425 A5 JP 2006506425A5 JP 2004552562 A JP2004552562 A JP 2004552562A JP 2004552562 A JP2004552562 A JP 2004552562A JP 2006506425 A5 JP2006506425 A5 JP 2006506425A5
Authority
JP
Japan
Prior art keywords
methyl
ethyl
formula
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004552562A
Other languages
English (en)
Other versions
JP2006506425A (ja
Filing date
Publication date
Priority claimed from DE10253220A external-priority patent/DE10253220A1/de
Application filed filed Critical
Publication of JP2006506425A publication Critical patent/JP2006506425A/ja
Publication of JP2006506425A5 publication Critical patent/JP2006506425A5/ja
Pending legal-status Critical Current

Links

Claims (10)

  1. 一般式Ｉの化合物。
    Figure 2006506425
     (式中、nは1、2または3のいずれかを表し、
    R1は-C1-C4-アルキルを表し、
    R2、R3及びR4は同一でも異なっていてもよく、水素、-C1-C4-アルキル、-OH、-O-C1-C4-アルキル、-C1-C4-アルキレン-ハロゲン、-C1-C4-アルキレン-OH、-C1-C4-アルキレン-O-C1-C4-アルキル、-CF3、-CHF2、-NH2、-NH(C1-C4-アルキル)、-N(C1-C4-アルキル)2、ハロゲン、-COOH、-COO-C1-C4-アルキル、-NHCO-C1-C4-アルキル、-NHSO2-C1-C4-アルキル、-SO2NH2のいずれかを表す。）
  2. 式中、nが1または2を表し、
    R1がメチルもしくはエチルを表し、
    R2、R3及びR4は同一でも異なっていてもよく、水素、メチル、エチル、-OH、メトキシ、エトキシ、-CH2F、-CH2Cl、-CH2Br、-CH2CH2F、−CH2CH2Cl、-CH2CH2Br、-CH2OH、-CH2CH2OH、-CH2Oメチル、−CH2CH2Oメチル、−CH2Oエチル、-CH2CH2Oエチル、-CF3、-CHF2、-NH2、-NHメチル、-NHエチル、-N(メチル)2、-N(エチル)2、フッ素、塩素、臭素、-COOH、−COOメチル、-COOエチル、-NHCO-メチル、−NHCO-エチル、-NHSO2-メチル、-NHSO2-エチルのいずれかで表される、請求項1記載の式Ｉの化合物。
  3. 式中、nが1または2を表し、
    R1がメチルもしくはエチルを表し、
    R2、R3及びR4は同一でも異なっていてもよく、水素、メチル、エチル、-OH、メトキシ、エトキシ、-CH2F、-CH2CH2F、-CH2OH、-CH2CH2OH、-CH2Oメチル、−CH2CH2Oメチル、−CH2Oエチル、-CH2CH2Oエチル、-CF3、-CHF2のいずれかで表される、請求項1または2に記載の式Ｉの化合物。
  4. 式中、nが1または2を表し、
    R1がメチルもしくはエチルを表し、
    R2、R3及びR4は同一でも異なっていてもよく、水素、メチル、エチル、-OH、メトキシ、エトキシ、-CF3、-CHF2のいずれかで表される、請求項1〜3のいずれか1項に記載の式Ｉの化合物。
  5. 式中、nが1または2を表し、
    R1がメチルもしくはエチルを表し、
    R2、R3及びR4は同一でも異なっていてもよく、水素、メチル、エチル、-OH、-CF3のいずれかで表される、請求項1〜4のいずれか1項に記載の式Ｉの化合物。
  6. 式中、nが1または2を表し、
    R1がメチルもしくはエチルを表し、
    R2、R3及びR4は同一でも異なっていてもよく、水素、メチル、-OHのいずれかで表される、請求項1〜5のいずれか1項に記載の式Ｉの化合物。
  7. 式中、nが1または2を表し、
    R1がメチルもしくはエチルを表し、
    R2が水素を表し、
    R3及びR4は同一でも異なっていてもよく、水素、メチル、-OHのいずれかで表される、請求項1〜6のいずれか1項に記載の式Ｉの化合物。
  8. 単一光学異性体、単一鏡像異性体混合物またはラセミ体の形を取り、また、遊離塩基もしくは薬理学的に許容しうる酸との対応する酸付加塩の形を取る、請求項1〜7のいずれか1項に記載の式Ｉの化合物。
  9. 治療上有効量のベータミメティックの投与が治療効果を及ぼすような疾患の治療用医薬組成物を調製するための請求項1〜8のいずれか1項に記載の一般式Ｉの化合物の使用。
  10. 請求項1〜8のいずれか1項に記載の式Ｉの化合物を1つ又はそれ以上含むことを特徴とする医薬製剤。
JP2004552562A 2002-11-15 2003-11-11 新規ジヒドロキシ−メチルフェニル誘導体、その製造方法及び薬剤としてのその使用 Pending JP2006506425A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10253220A DE10253220A1 (de) 2002-11-15 2002-11-15 Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
PCT/EP2003/012566 WO2004046083A1 (de) 2002-11-15 2003-11-11 Neue dihydroxy-methyl-phenyl-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel

Publications (2)

Publication Number Publication Date
JP2006506425A JP2006506425A (ja) 2006-02-23
JP2006506425A5 true JP2006506425A5 (ja) 2007-01-11

Family

ID=32185693

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004552562A Pending JP2006506425A (ja) 2002-11-15 2003-11-11 新規ジヒドロキシ−メチルフェニル誘導体、その製造方法及び薬剤としてのその使用

Country Status (7)

Country Link
US (1) US7135500B2 (ja)
EP (1) EP1562892A1 (ja)
JP (1) JP2006506425A (ja)
AU (1) AU2003282094A1 (ja)
CA (1) CA2506109A1 (ja)
DE (1) DE10253220A1 (ja)
WO (1) WO2004046083A1 (ja)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US7402608B2 (en) * 2002-12-10 2008-07-22 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
DE102004003428A1 (de) * 2004-01-23 2005-08-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Beta-2-Agonisten, und deren Verwendung als Arzneimittel
US7220742B2 (en) * 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
KR20080036632A (ko) 2005-08-08 2008-04-28 아젠터 디스커버리 리미티드 바이시클로[2.2.1]헵트-7-일아민 유도체 및 이들의 용도
CA2619402C (en) * 2005-08-15 2015-02-03 Boehringer Ingelheim International Gmbh Method for producing betamimetics
CA2625664C (en) 2005-10-21 2016-01-05 Novartis Ag Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
PT2322525E (pt) 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
CA2664378A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as pi3k lipid kinase inhibitors
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
BRPI0718915A2 (pt) * 2006-11-15 2013-12-03 Virochem Pharma Inc Análogos de tiofeno para o tratamento ou prevenção de infecções por flavivírus
AU2007342223B2 (en) 2007-01-10 2011-02-24 Irm Llc Compounds and compositions as channel activating protease inhibitors
ES2361595T3 (es) 2007-05-07 2011-06-20 Novartis Ag Compuestos orgánicos.
MX2010006421A (es) 2007-12-10 2010-06-25 Novartis Ag Compuestos organicos.
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
EP2300010B1 (en) 2008-06-10 2015-03-04 Novartis AG Pyrazine derivatives as epithelial sodium channel blockers
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
EA019441B1 (ru) 2008-12-30 2014-03-31 Палмаджен Терепьютикс (Инфлеммейшн) Лимитед Сульфонамиды, предназначенные для лечения респираторных нарушений
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
CA2770873A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
IN2012DN01961A (ja) 2009-08-17 2015-08-21 Intellikine Llc
EP2467383A1 (en) 2009-08-20 2012-06-27 Novartis AG Heterocyclic oxime compounds
WO2011050325A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
SG192795A1 (en) 2011-02-25 2013-09-30 Irm Llc Compounds and compositions as trk inhibitors
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
ES2691650T3 (es) 2011-09-15 2018-11-28 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
RU2660354C2 (ru) 2012-04-03 2018-07-05 Новартис Аг Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
KR20160141855A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피라진 유도체
PT3134396T (pt) 2014-04-24 2019-12-16 Novartis Ag Derivados de amino piridina como inibidores da fosfatidilinositol 3-quinase
PL3134395T3 (pl) 2014-04-24 2018-07-31 Novartis Ag Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CN107207510B (zh) 2014-07-31 2019-11-29 诺华股份有限公司 联合疗法
CN113891744A (zh) 2019-06-10 2022-01-04 诺华股份有限公司 用于治疗cf、copd和支气管扩张的吡啶和吡嗪衍生物
KR20220052934A (ko) 2019-08-28 2022-04-28 노파르티스 아게 치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1543372A1 (de) * 1966-10-18 1971-04-01 Boehringer Sohn Ingelheim Verfahren zur Herstellung von o-substituierten 3,4-Dioxyphenylalkanolaminen
US3969410A (en) * 1972-01-12 1976-07-13 Boehringer Ingelheim Gmbh 1-(2'-Alkyl-3',4'-dihydroxy-phenyl)-2-(phenylalkyl-amino)-alkanols-(1) and salts thereof
US4042713A (en) * 1966-10-18 1977-08-16 Boehringer Ingelheim Gmbh Pharmaceutical compositions containing a 1-(2-alkyl-3,4-dihydroxy-phenyl)-2-(phenylalkyl-amino)-alkanol-(1) and method of use
NO162113C (no) * 1984-04-17 1989-11-08 Glaxo Group Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive fenetanolaminforbindelser.
US5223614A (en) * 1987-12-19 1993-06-29 Boehringer Ingelheim Gmbh New quaternary ammonium compounds, their preparation and use
HUP0300832A2 (hu) 2000-04-27 2003-08-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Új, lassú hatású bétamimetikumok, eljárás előállításukra és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények

Similar Documents

Publication Publication Date Title
JP2006506425A5 (ja)
JP2016534063A5 (ja)
JP2017528503A5 (ja)
JP2021063088A5 (ja)
JP2018518537A5 (ja)
JP2006526590A5 (ja)
JP2005516067A5 (ja)
JP2005525323A5 (ja)
JP2010503688A5 (ja)
JP2008512408A5 (ja)
JP2009541209A5 (ja)
JP2003531118A5 (ja)
JP2005525322A5 (ja)
JP2014515351A5 (ja)
JP2006182786A5 (ja)
JP2012525393A5 (ja)
JP2013542247A5 (ja)
JP2006526031A5 (ja)
JP2014500861A5 (ja)
JP2008513510A5 (ja)
JP2007525533A5 (ja)
JP2005524605A5 (ja)
JP2012532883A5 (ja)
JP2010526827A5 (ja)
RU2007138582A (ru) Пероральные дозированные формы производных гемцитабина